317 related articles for article (PubMed ID: 34890567)
1. Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn's disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial.
Schulberg JD; Wright EK; Holt BA; Hamilton AL; Sutherland TR; Ross AL; Vogrin S; Miller AM; Connell WC; Lust M; Ding NS; Moore GT; Bell SJ; Shelton E; Christensen B; De Cruz P; Rong YJ; Kamm MA
Lancet Gastroenterol Hepatol; 2022 Apr; 7(4):318-331. PubMed ID: 34890567
[TBL] [Abstract][Full Text] [Related]
2. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Colombel JF; Panaccione R; Bossuyt P; Lukas M; Baert F; Vaňásek T; Danalioglu A; Novacek G; Armuzzi A; Hébuterne X; Travis S; Danese S; Reinisch W; Sandborn WJ; Rutgeerts P; Hommes D; Schreiber S; Neimark E; Huang B; Zhou Q; Mendez P; Petersson J; Wallace K; Robinson AM; Thakkar RB; D'Haens G
Lancet; 2017 Dec; 390(10114):2779-2789. PubMed ID: 29096949
[TBL] [Abstract][Full Text] [Related]
3. Crohn's disease management after intestinal resection: a randomised trial.
De Cruz P; Kamm MA; Hamilton AL; Ritchie KJ; Krejany EO; Gorelik A; Liew D; Prideaux L; Lawrance IC; Andrews JM; Bampton PA; Gibson PR; Sparrow M; Leong RW; Florin TH; Gearry RB; Radford-Smith G; Macrae FA; Debinski H; Selby W; Kronborg I; Johnston MJ; Woods R; Elliott PR; Bell SJ; Brown SJ; Connell WR; Desmond PV
Lancet; 2015 Apr; 385(9976):1406-17. PubMed ID: 25542620
[TBL] [Abstract][Full Text] [Related]
4. Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial.
van Linschoten RCA; Jansen FM; Pauwels RWM; Smits LJT; Atsma F; Kievit W; de Jong DJ; de Vries AC; Boekema PJ; West RL; Bodelier AGL; Gisbertz IAM; Wolfhagen FHJ; Römkens TEH; Lutgens MWMD; van Bodegraven AA; Oldenburg B; Pierik MJ; Russel MGVM; de Boer NK; Mallant-Hent RC; Ter Borg PCJ; van der Meulen-de Jong AE; Jansen JM; Jansen SV; Tan ACITL; van der Woude CJ; Hoentjen F;
Lancet Gastroenterol Hepatol; 2023 Apr; 8(4):343-355. PubMed ID: 36736339
[TBL] [Abstract][Full Text] [Related]
5. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
Danese S; Vermeire S; D'Haens G; Panés J; Dignass A; Magro F; Nazar M; Le Bars M; Lahaye M; Ni L; Bravata I; Lavie F; Daperno M; Lukáš M; Armuzzi A; Löwenberg M; Gaya DR; Peyrin-Biroulet L;
Lancet Gastroenterol Hepatol; 2022 Apr; 7(4):294-306. PubMed ID: 35120656
[TBL] [Abstract][Full Text] [Related]
6. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial.
Sandborn WJ; Panés J; Danese S; Sharafali Z; Hassanali A; Jacob-Moffatt R; Eden C; Daperno M; Valentine JF; Laharie D; Baía C; Atreya R; Panaccione R; Rydzewska G; Aguilar H; Vermeire S;
Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):43-55. PubMed ID: 36240801
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.
Hanauer S; Liedert B; Balser S; Brockstedt E; Moschetti V; Schreiber S
Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):816-825. PubMed ID: 34388360
[TBL] [Abstract][Full Text] [Related]
8. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.
Noor NM; Lee JC; Bond S; Dowling F; Brezina B; Patel KV; Ahmad T; Banim PJ; Berrill JW; Cooney R; De La Revilla Negro J; de Silva S; Din S; Durai D; Gordon JN; Irving PM; Johnson M; Kent AJ; Kok KB; Moran GW; Mowat C; Patel P; Probert CS; Raine T; Saich R; Seward A; Sharpstone D; Smith MA; Subramanian S; Upponi SS; Wiles A; Williams HRT; van den Brink GR; Vermeire S; Jairath V; D'Haens GR; McKinney EF; Lyons PA; Lindsay JO; Kennedy NA; Smith KGC; Parkes M;
Lancet Gastroenterol Hepatol; 2024 May; 9(5):415-427. PubMed ID: 38402895
[TBL] [Abstract][Full Text] [Related]
9. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
Kennedy NA; Heap GA; Green HD; Hamilton B; Bewshea C; Walker GJ; Thomas A; Nice R; Perry MH; Bouri S; Chanchlani N; Heerasing NM; Hendy P; Lin S; Gaya DR; Cummings JRF; Selinger CP; Lees CW; Hart AL; Parkes M; Sebastian S; Mansfield JC; Irving PM; Lindsay J; Russell RK; McDonald TJ; McGovern D; Goodhand JR; Ahmad T;
Lancet Gastroenterol Hepatol; 2019 May; 4(5):341-353. PubMed ID: 30824404
[TBL] [Abstract][Full Text] [Related]
10. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease.
Gordon M; Taylor K; Akobeng AK; Thomas AG
Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD010233. PubMed ID: 25081347
[TBL] [Abstract][Full Text] [Related]
11. Self-expandable metal stents versus endoscopic balloon dilation for the treatment of strictures in Crohn's disease (ProtDilat study): an open-label, multicentre, randomised trial.
Loras C; Andújar X; Gornals JB; Sanchiz V; Brullet E; Sicilia B; Martín-Arranz MD; Naranjo A; Barrio J; Dueñas C; Foruny JR; Busquets D; Monfort D; Pineda JR; González-Huix F; Pérez-Roldán F; Pons V; González B; Reyes Moreno J; Sainz E; Guardiola J; Bosca-Watts MM; Fernández-Bañares F; Mayor V; Esteve M;
Lancet Gastroenterol Hepatol; 2022 Apr; 7(4):332-341. PubMed ID: 35065738
[TBL] [Abstract][Full Text] [Related]
12. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial.
Mowat C; Arnott I; Cahill A; Smith M; Ahmad T; Subramanian S; Travis S; Morris J; Hamlin J; Dhar A; Nwokolo C; Edwards C; Creed T; Bloom S; Yousif M; Thomas L; Campbell S; Lewis SJ; Sebastian S; Sen S; Lal S; Hawkey C; Murray C; Cummings F; Goh J; Lindsay JO; Arebi N; Potts L; McKinley AJ; Thomson JM; Todd JA; Collie M; Dunlop MG; Mowat A; Gaya DR; Winter J; Naismith GD; Ennis H; Keerie C; Lewis S; Prescott RJ; Kennedy NA; Satsangi J;
Lancet Gastroenterol Hepatol; 2016 Dec; 1(4):273-282. PubMed ID: 28404197
[TBL] [Abstract][Full Text] [Related]
13. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
Sands BE; Irving PM; Hoops T; Izanec JL; Gao LL; Gasink C; Greenspan A; Allez M; Danese S; Hanauer SB; Jairath V; Kuehbacher T; Lewis JD; Loftus EV; Mihaly E; Panaccione R; Scherl E; Shchukina OB; Sandborn WJ;
Lancet; 2022 Jun; 399(10342):2200-2211. PubMed ID: 35691323
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study.
Bouhnik Y; Carbonnel F; Laharie D; Stefanescu C; Hébuterne X; Abitbol V; Nachury M; Brixi H; Bourreille A; Picon L; Bourrier A; Allez M; Peyrin-Biroulet L; Moreau J; Savoye G; Fumery M; Nancey S; Roblin X; Altwegg R; Bouguen G; Bommelaer G; Danese S; Louis E; Zappa M; Mary JY;
Gut; 2018 Jan; 67(1):53-60. PubMed ID: 28119352
[TBL] [Abstract][Full Text] [Related]
15. Long term follow up of through-the-scope balloon dilation as compared to strictureplasty and bowel resection of intestinal strictures in crohn's disease.
Krauss E; Agaimy A; Gottfried A; Maiss J; Weidinger T; Albrecht H; Hartmann A; Hohenberger W; Neurath MF; Kessler H; Mudter J
Int J Clin Exp Pathol; 2014; 7(11):7419-31. PubMed ID: 25550777
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the endoscopic treatment with topical prednisolone administration for intestinal strictures in Crohn's disease.
Feleshtynskiy Y; Mylianovska A; Pirogovsky V; Dyadyk O
Pol Przegl Chir; 2021 Sep; 94(1):28-33. PubMed ID: 35195075
[TBL] [Abstract][Full Text] [Related]
17. Endoscopic Dilatation of Crohn's Anastomotic Strictures is Effective in the Long Term, and Escalation of Medical Therapy Improves Outcomes in the Biologic Era.
Ding NS; Yip WM; Choi CH; Saunders B; Thomas-Gibson S; Arebi N; Humphries A; Hart A
J Crohns Colitis; 2016 Oct; 10(10):1172-8. PubMed ID: 26971054
[TBL] [Abstract][Full Text] [Related]
18. The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial.
Yanai H; Levine A; Hirsch A; Boneh RS; Kopylov U; Eran HB; Cohen NA; Ron Y; Goren I; Leibovitzh H; Wardi J; Zittan E; Ziv-Baran T; Abramas L; Fliss-Isakov N; Raykhel B; Gik TP; Dotan I; Maharshak N
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):49-59. PubMed ID: 34739863
[TBL] [Abstract][Full Text] [Related]
19. Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn's disease.
Candia R; Bravo-Soto GA; Monrroy H; Hernandez C; Nguyen GC
Cochrane Database Syst Rev; 2020 Aug; 8(8):CD012328. PubMed ID: 32746500
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of drug and endoscopic treatment of Crohn's disease strictures: A systematic review.
Schulberg JD; Wright EK; Holt BA; Wilding HE; Hamilton AL; Ross AL; Kamm MA
J Gastroenterol Hepatol; 2021 Feb; 36(2):344-361. PubMed ID: 33150989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
